KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Income (2016 - 2025)

Supernus Pharmaceuticals has reported Non Operating Income over the past 15 years, most recently at $2.0 million for Q4 2025.

  • Quarterly Non Operating Income fell 59.35% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.3 million through Dec 2025, down 18.21% year-over-year, with the annual reading at $13.3 million for FY2025, 18.21% down from the prior year.
  • Non Operating Income was $2.0 million for Q4 2025 at Supernus Pharmaceuticals, down from $2.3 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $12.8 million in Q1 2022 and troughed at -$4.7 million in Q4 2022.
  • The 5-year median for Non Operating Income is $2.2 million (2025), against an average of $1.9 million.
  • Year-over-year, Non Operating Income plummeted 273.16% in 2021 and then skyrocketed 711.52% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$4.0 million in 2021, then dropped by 15.39% to -$4.7 million in 2022, then soared by 142.53% to $2.0 million in 2023, then surged by 150.6% to $5.0 million in 2024, then crashed by 59.35% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Non Operating Income are $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $4.5 million (Q2 2025).